SCHEMBL21032547

SCHEMBL21032547

Cc1c(Cc2cccc3c2CCS3(=O)=O)c2cc(F)ccc2n1CC(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 20/20 1.00
PTGIR P43119 1/20 0.54
PTGDR Q13258 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21032403 0.85 PTGDR2 (1.00) PTGDR2PTGIRPTGDR
SCHEMBL21032915 0.84 PTGDR2 (0.73) PTGDR2PTGIRPTGDR
SCHEMBL21031850 0.81 PTGDR2 (0.73) PTGDR2
SCHEMBL21032460 0.80 PTGDR2 (1.00) PTGDR2
SCHEMBL21032194 0.80 PTGDR2 (1.00) PTGDR2
SCHEMBL1783309 0.78 PTGDR2 (0.71) PTGDR2PTGIRPTGDR
SCHEMBL21032402 0.77 PTGDR2 (0.83) PTGDR2PTGDR
SCHEMBL21032571 0.77 PTGDR2 (0.67) PTGDR2PTGIRPTGDR
SCHEMBL1784687 0.76 PTGDR2 (0.68) PTGDR2PTGIRPTGDR
SCHEMBL1784567 0.75 PTGDR2 (0.67) PTGDR2PTGIRPTGDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3489233-B1 INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) 2022-01-12 EP disclosed
US-10800765-B2 Indole derivative used as CRTH2 inhibitor CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2020-10-13 US disclosed
US-20190248770-A1 INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2019-08-15 US disclosed
EP-3489233-A1 INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2019-05-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190248770-A1 INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR NR3C2, CRHR2, TPH2 PTGDR2 97/4885PTGIR 541/4885PTGDR 204/4885
US-10800765-B2 Indole derivative used as CRTH2 inhibitor NR3C2, CRHR2, TPH2 PTGDR2 97/4885PTGIR 541/4885PTGDR 204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.